OEA (Oleoylethanolamide)
An endogenous lipid amide that is not produced by cannabis but often misidentified as one.
OEA is frequently mislabeled as a cannabis terpene, but it isn't one—cannabis doesn't make it. OEA is a lipid your body produces in the small intestine. It's biochemically interesting because it shares metabolic pathways with anandamide (an endocannabinoid), but that connection doesn't make it part of cannabis. If a strain or product claims to be "high in OEA," that's a sign someone doesn't understand basic chemistry.
What OEA Actually Is
OEA (oleoylethanolamide) is not a terpene and is not produced by cannabis. This is the most important clarification upfront.
OEA is a lipid amide — specifically, the ethanolamide of oleic acid, an 18-carbon monounsaturated fatty acid. Strong evidence[1] It is synthesized on demand in mammalian cells, especially intestinal epithelial cells, from membrane phospholipid precursors via the NAPE-PLD enzyme pathway. Strong evidence[2][3] The same pathway that produces anandamide (the endogenous cannabinoid) also produces OEA, which is why the two are chemically related, but OEA does not bind cannabinoid receptors at physiologically meaningful affinities. Strong evidence[3]
OEA is broken down primarily by the enzyme FAAH (fatty acid amide hydrolase), which also degrades anandamide and other N-acylethanolamines. Strong evidence[2][3]
Terpenes, by contrast, are hydrocarbons built from isoprene (C₅H₈) building blocks and are characteristic plant secondary metabolites. Cannabis produces many terpenes (myrcene, limonene, beta-caryophyllene), but OEA is not among them.
Molecular Targets and Mechanism
OEA's primary molecular target is PPAR-α (peroxisome proliferator-activated receptor alpha), a nuclear receptor that controls fatty acid oxidation and energy homeostasis. Strong evidence[4] OEA binds PPAR-α with sub-micromolar affinity and activates receptor-dependent signaling pathways that reduce food intake and increase fatty acid oxidation. Strong evidence[4]
At higher concentrations, OEA also activates GPR119 (a G-protein coupled receptor involved in glucose and lipid sensing) and TRPV1 (the capsaicin receptor). Strong evidence[3] However, PPAR-α activation is considered its primary physiological role.
This mechanism is distinct from cannabinoid-receptor signaling, even though both OEA and anandamide share metabolic enzymes. OEA's biology centers on nutrient sensing and satiety, not on the endocannabinoid system.
Where OEA Is Found
OEA is endogenous to mammals—it is synthesized by animal cells, not by plants.
In animals: The highest concentrations are in the jejunum and duodenum of the small intestine. Strong evidence[1] Measurable levels are also found in the liver, brain, adipose tissue, and blood plasma. Strong evidence[2] Tissue levels of OEA rise after eating (especially after consuming dietary fat) and fall during fasting, reflecting its role as a satiety signal. Strong evidence[1][6]
Dietary oleic acid—abundant in olive oil and other high-oleate fats—serves as a substrate for intestinal OEA synthesis, which is one reason high-oleate diets are studied in relation to appetite control and satiety. Strong evidence[4][6]
In cannabis: OEA is not present in cannabis flower, trichomes, or extracts in any meaningful sense. Cannabis plants produce phytocannabinoids and terpenes; OEA-class lipids are animal metabolites only.
Effects Research: Preclinical vs. Human Evidence
Preclinical evidence (strong in rodents):
OEA reliably reduces food intake, prolongs the time between meals, promotes lipolysis, and increases fatty acid oxidation in rats and mice. Strong evidence[4][5] These effects are abolished in PPAR-α knockout animals, establishing the mechanism causally. Strong evidence[4] This is robust, replicable evidence in animal models.
Human evidence (weak and limited):
Small clinical studies have measured circulating OEA levels in relation to obesity, eating disorders, and dietary fat intake, with inconsistent results. Weak / limited[6][7] A handful of randomized controlled trials have tested OEA-precursor supplements (such as N-oleoyl-phosphatidylethanolamine, marketed under brand names like Riduzone) for appetite suppression and weight loss. These trials generally report modest and short-lived reductions in food intake, but the clinical significance remains unclear. Weak / limited[7] No large, long-term trials have established that OEA or its precursors are effective weight-loss agents.
Why the gap? Animal models of appetite are very different from human eating behavior. Rodents have simpler cognitive and social influences on food intake; human weight loss is driven by behavior, psychology, environment, and genetics as much as by satiety biochemistry. Preclinical satiety signals often do not translate to clinically meaningful weight loss in humans.
Interaction with cannabis: Because FAAH degrades both anandamide and OEA, experimental FAAH inhibitors raise OEA alongside anandamide. Strong evidence[3] This is biochemically interesting but does not make OEA a cannabis compound or a reason to call OEA a terpene.
Strains and Products Claiming High OEA
No cannabis strain is "high in OEA." Cannabis plants do not synthesize OEA. If a product, strain description, or marketing page claims a cannabis strain is "rich in OEA" or "dominant in OEA," that is a red flag for either:
- A fundamental misunderstanding of plant biochemistry, or
- Deliberate misinformation.
Such claims have no scientific basis and should not influence purchasing decisions. Strain effects are driven by genuine cannabis compounds: phytocannabinoids (THC, CBD, CBG, etc.) and plant terpenes (myrcene, limonene, beta-caryophyllene, pinene, etc.)—not by animal-synthesized lipid amides.
If you are interested in cannabis compounds that genuinely interact with appetite or metabolism, focus on documented phytocannabinoids such as THC and CBD, which have measurable human research.
OEA's Chemical Family: N-Acylethanolamines
OEA belongs to the chemical family of N-acylethanolamines (NAEs)—lipid amides formed by linking a long-chain fatty acid to ethanolamine. This family includes:
- Anandamide (AEA) — arachidonic acid + ethanolamine; the primary endogenous CB1/CB2 agonist and a key player in the endocannabinoid system. Strong evidence[2]
- Palmitoylethanolamide (PEA) — palmitic acid + ethanolamine; has anti-inflammatory and neuroprotective effects; also activates PPAR-α. Strong evidence[5]
- Stearoylethanolamide (SEA) — stearic acid + ethanolamine.
- 2-Arachidonoylglycerol (2-AG) — the other major endocannabinoid (a glycerol ester, not an ethanolamide; a CB1/CB2 agonist).
All NAEs share the FAAH/NAPE-PLD metabolic machinery, which is why pharmacological or dietary interventions that perturb one often perturb the others. Strong evidence[2][3] However, their biological effects differ: anandamide and 2-AG are cannabinoid-receptor agonists, while OEA and PEA work primarily through PPAR-α and other non-cannabinoid receptors.
None of these compounds are terpenes, and only anandamide and 2-AG are part of the endocannabinoid system proper.
Sources
- Peer-reviewed Rodríguez de Fonseca F, Navarro M, Gómez R, et al. An anorexic lipid mediator regulated by feeding. Nature. 2001;414(6860):209–212.
- Peer-reviewed Piomelli D. A fatty gut feeling. Trends in Endocrinology & Metabolism. 2013;24(7):332–341.
- Peer-reviewed Hansen HS, Diep TA. N-acylethanolamines, anandamide and food intake. Biochemical Pharmacology. 2009;78(6):553–560.
- Peer-reviewed Fu J, Gaetani S, Oveisi F, et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature. 2003;425(6953):90–93.
- Peer-reviewed Lo Verme J, Fu J, Astarita G, et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Molecular Pharmacology. 2005;67(1):15–19.
- Peer-reviewed Schwartz GJ, Fu J, Astarita G, et al. The lipid messenger OEA links dietary fat intake to satiety. Cell Metabolism. 2008;8(4):281–288.
- Peer-reviewed Laleh P, Yaser K, Alireza O. Oleoylethanolamide: a novel pharmaceutical agent in the management of obesity—an updated review. Journal of Cellular Physiology. 2019;234(6):7893–7902.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Acidic vs Neutral Cannabinoids — The chemistry difference between what the plant makes (THCA, CBDA) and what you actually c...
- Spice / K2: Why Synthetic Cannabinoids Are Not Weed — Synthetic cannabinoids are lab-made CB1 receptor agonists, structurally and pharmacologica...
- TRPV1 Receptor and Cannabinoids — An ion channel activated by cannabinoids and capsaicin; mostly studied in cells and animal...